SYNTHETIC DEMONSTRATION — no real student or patient. Not a medical device.

Medication

Mounjaro (Tirzepatide): Uses, Side Effects, and How It Works

Mounjaro (tirzepatide) is a once-weekly injectable medication FDA-approved in May 2022 for adults with type 2 diabetes. It is the first dual GIP and GLP-1 receptor agonist — activating two incretin pathways simultaneously to lower blood sugar and reduce appetite. In clinical trials, it reduced HbA1c by up to 2.30 percentage points and produced meaningful weight loss. The most common side effects are nausea, diarrhea, and vomiting, especially during dose increases.

Written by Gale Editorial · grounded in the cited clinical sources below · Updated 2026-06-15. How we write.

Drug facts

Generic name:
tirzepatide
Class:
Dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist
Brand names:
Mounjaro, Zepbound
How it's taken:
Subcutaneous injection, once weekly

Talk to a clinician

Gale can match you with a clinician licensed in your state — the honest cost shown before you book.

Find care →

What Mounjaro Is

Mounjaro is the brand name for tirzepatide, manufactured by Eli Lilly and Company. The FDA approved it on May 13, 2022, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus 1.

Tirzepatide is the first approved dual GIP and GLP-1 receptor agonist — meaning it simultaneously activates two incretin pathways, distinguishing it from GLP-1-only drugs such as semaglutide (Ozempic, Wegovy).

The same molecule is sold as Zepbound under a separate FDA approval for chronic weight management. Mounjaro and Zepbound are identical in active ingredient; the distinction is the approved indication.

How Mounjaro Works: The Dual-Receptor Mechanism

The gut releases two incretin hormones after a meal: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Both signal the pancreas to release insulin; type 2 diabetes impairs these responses.

Tirzepatide is a single synthetic molecule engineered to bind both receptors simultaneously. At the GLP-1 receptor, it stimulates insulin in a glucose-dependent way, suppresses glucagon, slows gastric emptying (extending fullness), and reduces appetite via brain signaling. At the GIP receptor, it further amplifies insulin release, promotes fat metabolism, and may support pancreatic beta-cell health 5.

This dual action is believed to explain tirzepatide's superior outcomes versus GLP-1-only agents in head-to-head trials 23.

Clinical Trial Results

SURPASS-2 (direct comparison vs. semaglutide, n=1,879, 40 weeks): At 40 weeks, mean HbA1c fell by 2.01 percentage points (5 mg), 2.24 pp (10 mg), and 2.30 pp (15 mg) with tirzepatide, compared with 1.86 pp for semaglutide 1 mg — superiority at every dose 2. Sixty percent of patients on 15 mg tirzepatide achieved the composite endpoint of HbA1c ≤6.5% plus ≥10% weight loss with no severe hypoglycemia, versus 22% on semaglutide.

SURMOUNT-5 (head-to-head weight loss vs. Wegovy, n=750, 72 weeks): In a 2025 trial of tirzepatide versus semaglutide 2.4 mg in adults with obesity but without type 2 diabetes, tirzepatide produced mean weight loss of 20.2% versus 13.7% for semaglutide — a 47% greater relative reduction. Waist circumference fell 18.4 cm versus 13.0 cm 3.

A 2024 meta-analysis of 12 randomized controlled trials (n=11,758) confirmed tirzepatide's dose-dependent efficacy and its predominantly GI-related side-effect profile 4.

Dosing Schedule

Mounjaro is injected once weekly by subcutaneous injection into the abdomen, thigh, or upper arm. The injection can be given at any time of day, with or without food. The dosing ladder is:

  • 2.5 mg once weekly for the first 4 weeks (initiation dose; not intended for glycemic control)
  • 5 mg once weekly after week 4
  • Dose increases by 2.5 mg every 4 weeks as tolerated
  • Maximum dose: 15 mg once weekly

Maintenance doses for type 2 diabetes are 5 mg, 10 mg, or 15 mg. The slow titration schedule is designed to minimize gastrointestinal side effects during adjustment 1. If a dose is missed, it can be taken within 4 days (96 hours) of the scheduled day; if more than 4 days have passed, that dose is skipped and the next scheduled dose is taken.

Side Effects

Common (gastrointestinal): The most frequently reported side effects across SURPASS trials are nausea, diarrhea, vomiting, and constipation — most prominent during the first weeks and after each dose increase, improving as the body adjusts. GI symptoms were the primary reason for discontinuation; approximately 6% of tirzepatide-treated participants stopped due to adverse events 4.

Hypoglycemia: Low blood sugar risk is highest when tirzepatide is combined with insulin or sulfonylureas. Used alone, hypoglycemia is uncommon because insulin stimulation is glucose-dependent.

Less common: injection-site reactions; modest heart rate increase (consistent with the drug class); acute kidney injury (rare, typically from dehydration); gallbladder disease associated with rapid weight loss.

Pancreatitis (rare): Confirmed acute pancreatitis occurred in approximately 0.23 patients per 100 years of exposure in clinical trials 1. Severe, persistent abdominal pain radiating to the back warrants prompt evaluation.

Black box warning — thyroid C-cell tumors: Tirzepatide caused thyroid C-cell tumors in rodents. Human relevance is unknown. Mounjaro is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It is not approved for type 1 diabetes and is not recommended during pregnancy 1.

Mounjaro vs. Zepbound vs. Ozempic: What Is the Difference?

| Drug | Brand | Indication | Mechanism | |---|---|---|---| | Tirzepatide | Mounjaro | Type 2 diabetes | Dual GIP + GLP-1 | | Tirzepatide | Zepbound | Chronic weight management | Dual GIP + GLP-1 | | Semaglutide | Ozempic | Type 2 diabetes | GLP-1 only | | Semaglutide | Wegovy | Chronic weight management | GLP-1 only |

Mounjaro and Zepbound are identical in active ingredient but carry different FDA-approved indications — as do Ozempic and Wegovy. Tirzepatide's dual GIP + GLP-1 mechanism activates a receptor pathway that semaglutide does not reach, which clinical data link to its greater average efficacy 23.

For weight loss without a type 2 diabetes diagnosis, Zepbound is the on-label choice. Insurance coverage typically follows the approved indication.

Cost and Savings Options

Mounjaro's list price is approximately $1,079 per monthly fill without insurance 6.

Eli Lilly Savings Card: Eligible patients with commercial insurance (excluding Medicare, Medicaid, and other government plans) may pay as little as $25 per fill. The card carries an annual savings cap of $1,950 and is valid through December 2026.

Zepbound self-pay via LillyDirect: For weight management without insurance coverage, Zepbound (same active ingredient) is available as a self-pay option at approximately $499 per month — meaningfully less than Mounjaro's list price.

Patient assistance: Lilly Cares Foundation provides Mounjaro at no cost for qualifying low-income or uninsured patients. Contact 1-800-LillyRx.

Insurance coverage for Mounjaro (type 2 diabetes indication) is generally more consistent than for Zepbound (weight management), as commercial plans and Medicare Part D have historically covered diabetes drugs more broadly than anti-obesity agents.

Common questions

What is Mounjaro approved for?

Mounjaro (tirzepatide) is FDA-approved as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus. It is not FDA-approved as Mounjaro for weight loss — the weight-management approval is under a separate brand name, Zepbound. Some clinicians prescribe Mounjaro off-label for weight loss in patients without diabetes.

How does Mounjaro differ from Ozempic?

Both target the GLP-1 receptor, but Mounjaro (tirzepatide) also activates the GIP receptor — a second incretin pathway. This dual action is believed to account for tirzepatide's greater average weight loss and HbA1c reduction versus semaglutide (Ozempic/Wegovy) in head-to-head trials. In the 2025 SURMOUNT-5 trial, tirzepatide produced 20.2% weight loss versus 13.7% for semaglutide over 72 weeks among people with obesity.

When do Mounjaro side effects start and how long do they last?

GI side effects — nausea, diarrhea, vomiting — are most common during the initial weeks of treatment and after each dose increase. For most people they improve within a few weeks as the body adjusts to the new dose. Starting at the lowest dose (2.5 mg) and titrating slowly is intended to minimize these effects. Eating smaller meals and avoiding high-fat foods can also help.

Can Mounjaro cause pancreatitis?

Acute pancreatitis has been reported with tirzepatide in clinical trials, though at a low rate (approximately 0.23 events per 100 years of patient exposure). Anyone taking Mounjaro who develops severe, persistent abdominal pain — especially pain that radiates to the back — should seek medical evaluation promptly, as this may indicate pancreatitis.

Is Mounjaro safe for people with thyroid conditions?

Mounjaro carries an FDA black box warning: in animal studies, tirzepatide caused thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). Whether this risk applies to humans is unknown. Mounjaro is contraindicated in individuals with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It is not contraindicated in people with common thyroid conditions such as hypothyroidism, unless those conditions involve MTC risk.

How much does Mounjaro cost without insurance?

Mounjaro's list price is approximately $1,079 per monthly fill. Patients with commercial insurance may access the Eli Lilly savings card to pay as little as $25 per fill, subject to an annual cap. Mounjaro is not available through the savings card for Medicare or Medicaid beneficiaries. The Lilly Cares Foundation offers patient assistance for low-income uninsured patients. Zepbound (same molecule, weight-management indication) is available at a lower self-pay price through LillyDirect.

Related conditions

GLP-1 and Muscle Loss: How to Protect Lean Mass

Related medications

Zepbound (Tirzepatide) for Weight Loss · Tirzepatide: Mounjaro and Zepbound Explained · Semaglutide vs Tirzepatide: How They Compare · Ozempic (Semaglutide): How It Works, Side Effects, and Cost · Wegovy (Semaglutide) for Weight Loss: Uses and Side Effects · Semaglutide: Ozempic, Wegovy, and Rybelsus Explained

Specialties

Primary Care: What a PCP Treats and When to See One

Talk to a clinician

Say what's going on in your own words. Gale finds a clinician licensed in your state and shows the real cost before you book.

Find care →

When to seek care

  • —Severe or persistent abdominal pain, especially if it radiates to the back — possible pancreatitis
  • —Signs of a serious allergic reaction: rash, swelling of the face or throat, difficulty breathing
  • —Vision changes or new or worsening eye problems (diabetic retinopathy can worsen with rapid glucose improvement)
  • —Symptoms of low blood sugar if also taking insulin or sulfonylureas: shakiness, rapid heartbeat, confusion, sweating
  • —Persistent vomiting or diarrhea leading to inability to keep fluids down — risk of dehydration and kidney injury
  • —A lump or swelling in the neck, hoarseness, or difficulty swallowing — possible thyroid concern

Call 911 or go to the nearest emergency room for difficulty breathing, throat swelling, or severe abdominal pain. For a poison control question, call 1-800-222-1222.

General health information, not medical advice. Synthetic demonstration content.

References

  1. 1.U.S. Food and Drug Administration (2022). MOUNJARO (tirzepatide) injection — Prescribing Information (NDA 215866). FDA / accessdata.fda.gov. link ✓FDA-approved indication (type 2 diabetes), drug class (dual GIP/GLP-1), contraindications (MTC, MEN2 black box), dosing schedule (2.5 mg start, titration every 4 weeks, 15 mg max), pancreatitis incidence in trials
  2. 2.Frías JP, Davies MJ, Rosenstock J, et al; SURPASS-2 Investigators (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. doi:10.1056/NEJMoa2107519 ✓SURPASS-2 head-to-head efficacy: HbA1c reduction (2.01, 2.24, 2.30 pp for 5/10/15 mg vs 1.86 pp semaglutide), weight loss advantage at every dose, composite endpoint results (60% vs 22% achieving HbA1c ≤6.5% + ≥10% weight loss on 15 mg vs semaglutide), n=1879, 40-week duration
  3. 3.Aronne LJ, Bade Horn D, le Roux CW, et al; SURMOUNT-5 Investigators (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. New England Journal of Medicine. doi:10.1056/NEJMoa2416394 ✓SURMOUNT-5 head-to-head: tirzepatide 20.2% vs semaglutide 13.7% weight loss at 72 weeks (n=750, adults with obesity without T2D); waist circumference −18.4 cm vs −13.0 cm; 47% greater relative weight reduction
  4. 4.Cai W, Zhang R, Yao Y, Wu Q, Zhang J (2024). Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Public Health. doi:10.3389/fpubh.2024.1277113 ✓Pooled efficacy and safety across 12 RCTs (n=11,758): dose-dependent weight loss, GI adverse events (nausea, vomiting, diarrhea) as most common side effects, approximately 6% discontinuation rate due to adverse events, serious adverse events similar to placebo
  5. 5.Farzam K, Patel P (2024). Tirzepatide. StatPearls [Internet]. StatPearls Publishing. link ✓Mechanism of action (GIP receptor effects on fat metabolism and beta-cell preservation, GLP-1 receptor effects on insulin secretion and appetite), contraindications, dosing titration schedule, monitoring recommendations (HbA1c every 3 months)
  6. 6.Eli Lilly and Company (2024). Mounjaro Savings & Coverage Information. mounjaro.lilly.com. link ✓Savings card eligibility (commercial insurance only, excludes Medicare/Medicaid), $25 per fill minimum with card, $1,950 annual savings cap, Lilly Cares patient assistance program contact

https://www.gale.care/drugs/mounjaro · 6 sources. General health information, not medical advice — synthetic demonstration content.